Lophius Biosciences, a privately held biotech company focusing on the development and marketing of innovative T cell based research tools and diagnostics for functional assessment of pathogen/disease-reactive T cells, announced the expansion of the management team.
Bernd Merkl, former site and product management leader of the GeneArt Centre of Excellence for Synthetic Biology within Thermo Fisher Scientific, has been appointed as co-CEO in order to drive the further development of the company in close collaboration with the current CEO Dr. Robert Phelps.
Lophius Biosciences, a privately held biotech company announced the expansion of the management team.
As former Product Management Leader within Thermo Fisher Scientific and Chief Business Officer at GeneArt AG Bernd Merkl was responsible for the commercial development of the worldwide synthetic gene business, the magnetic bead sample prep business and the synthetic biology kit and service business. Bernd Merkl will focus on the commercial operations including all marketing and sales activities of Lophius Biosciences to further drive the commercial success of the company together with the team.
“We are pleased that we were able to find the right candidate to expand our management board in the marketing and sales area. Bernd Merkl and Dr. Robert Phelps will form together a strong team to continue and accelerate the successful development of Lophius Biosciences in the future,” said Prof. Dr. Ralf Wagner, Chairman of the Supervisory Board.
“With the growing number of products in the T Cell Tool space and the diagnostic area, like T-Track CMV and the T-activated ImmunoScan Cocktail, Lophius Biosciences supports the scientific and clinical community to significantly improve the standard of diagnosis and ultimately the treatment of diseases associated with immunosuppression. I am really happy to be part of this exiting opportunity and the team,” said Bernd Merkl, co-CEO at Lophius Biosciences.
Lophius Biosciences
www.lophius.com
